Tango Therapeutics (NASDAQ:TNGX) Stock: Insider John Ketchum Sells 3,333 Shares

Tango Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director John Ketchum sold 3,333 shares at an average of $24.08, for about $80,259; he retained 21,604 shares after reducing his direct ownership by 13.37%.
  • Tango Therapeutics reported quarterly EPS of -$0.39, missing analyst expectations of -$0.35. Shares traded at $22.71 in Thursday’s session, within a 52-week range of $8.30 to $34.39.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $48.17; institutional investors and hedge funds own about 79% of the stock.
  • Five stocks we like better than Tango Therapeutics.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) Director John Ketchum sold 3,333 shares of the company's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $24.08, for a total transaction of $80,258.64. Following the sale, the director directly owned 21,604 shares of the company's stock, valued at approximately $520,224.32. This trade represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Tango Therapeutics Price Performance

NASDAQ TNGX traded up $0.82 during trading hours on Thursday, hitting $22.71. The company had a trading volume of 1,807,264 shares, compared to its average volume of 3,466,455. The firm's 50 day moving average is $23.51 and its 200 day moving average is $22.96. Tango Therapeutics, Inc. has a fifty-two week low of $8.30 and a fifty-two week high of $34.39. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of -16.58 and a beta of 1.26.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). On average, equities analysts anticipate that Tango Therapeutics, Inc. will post -1.47 EPS for the current year.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Tango Therapeutics during the 2nd quarter worth $388,826,000. TRV GP IV LLC acquired a new position in shares of Tango Therapeutics during the 2nd quarter worth about $120,181,383,000. Jupiter Topco LLC acquired a new position in Tango Therapeutics during the second quarter valued at approximately $157,989,000. Seven Fleet Capital Management LP grew its holdings in shares of Tango Therapeutics by 302.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company's stock valued at $95,661,000 after buying an additional 2,425,484 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Tango Therapeutics in the second quarter worth about $62,849,000. 78.99% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Wedbush lowered their price objective on shares of Tango Therapeutics from $45.00 to $40.00 and set an "outperform" rating for the company in a research report on Tuesday, November 10th. HC Wainwright reduced their target price on shares of Tango Therapeutics from $68.00 to $67.00 and set a "buy" rating on the stock in a research report on Tuesday, November 10th. William Blair started coverage on shares of Tango Therapeutics in a research report on Friday, October 16th. They set an "outperform" rating on the stock. Guggenheim upped their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Finally, Stifel Nicolaus set a $55.00 price target on shares of Tango Therapeutics in a report on Friday, October 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.17.

View Our Latest Report on TNGX

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

Read More

Insider Buying and Selling by Quarter for Tango Therapeutics (NASDAQ:TNGX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tango Therapeutics Right Now?

Before you consider Tango Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.

While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines